These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11394554)

  • 21. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
    Lampl C; You X; Limmroth V
    Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.
    Arroyo E; Grau C; Ramo-Tello C; Parra J; Sánchez-Soliño O;
    Eur Neurol; 2011; 65(2):59-67. PubMed ID: 21212677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.
    Devonshire V; Lapierre Y; Macdonell R; Ramo-Tello C; Patti F; Fontoura P; Suchet L; Hyde R; Balla I; Frohman EM; Kieseier BC;
    Eur J Neurol; 2011 Jan; 18(1):69-77. PubMed ID: 20561039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring medication adherence in multiple sclerosis using a novel web-based tool: A pilot study.
    Settle JR; Maloni HW; Bedra M; Finkelstein J; Zhan M; Wallin MT
    J Telemed Telecare; 2016 Jun; 22(4):225-33. PubMed ID: 26253748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MxA protein induction in MS patients treated with intramuscular IFNbeta-1a.
    Vallittu AM; Salmi AA; Erälinna JP;
    Neurol Sci; 2006 Feb; 26(6):438-43. PubMed ID: 16601938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
    Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of the FIM instrument in a trial of intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis.
    Granger CV; Wende K; Brownscheidle CM
    Am J Phys Med Rehabil; 2003 Jun; 82(6):427-36. PubMed ID: 12820784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study.
    Patti F; Pappalardo A; Montanari E; Pesci I; Barletta V; Pozzilli C
    J Neurol Sci; 2014 Feb; 337(1-2):180-5. PubMed ID: 24433926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Erbay Ö; Usta Yeşilbalkan Ö; Yüceyar N
    J Neurosci Nurs; 2018 Oct; 50(5):291-297. PubMed ID: 30138155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 39. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis.
    Cox D; Stone J
    J Neurosci Nurs; 2006 Jun; 38(3):167-71. PubMed ID: 16817668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
    Waubant E; Sloan R; Andersson PB; Goodkin D
    Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.